Equillium (FRA:0FY) FFO


FRA:0FY Equillium Inc FRA:0FY
33 GF Score
Price €2.54
GF Value €0.08
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Equillium FFO?

FFO (Funds from operations) only applies to REITs.

FRA:0FY
33GF Score
Equillium Inc FRA:0FY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Equillium (FRA:0FY) Overvalued in 2026?

Based on GuruFocus' analysis, Equillium stock appears to be overvalued. The current stock price of €2.54 is trading 3075% above its estimated GF Value™ of €0.08. GuruFocus considers Equillium to be Significantly Overvalued.

Key valuation signals for FRA:0FY:

  • FFO:
  • GF Value™: €0.08 vs. price of €2.54 (3075% above fair value)
  • GF Score™: 33/100 with 3 warning signs

No single metric tells the full story. See the FRA:0FY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Equillium Business Description

Other Exchanges EQ:USA0A4D:UK
Address 2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
33GF Score

Get the complete analysis for FRA:0FY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.54
Price
€0.08
GF Value